SOBI003
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sanfilippo Syndrome Type A (MPS IIIA)
Conditions
Sanfilippo Syndrome Type A (MPS IIIA)
Trial Timeline
Jun 19, 2018 → Oct 25, 2019
NCT ID
NCT03423186About SOBI003
SOBI003 is a phase 1/2 stage product being developed by Swedish Orphan Biovitrum for Sanfilippo Syndrome Type A (MPS IIIA). The current trial status is completed. This product is registered under clinical trial identifier NCT03423186. Target conditions include Sanfilippo Syndrome Type A (MPS IIIA).
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03811028 | Phase 1/2 | Completed |
| NCT03423186 | Phase 1/2 | Completed |
Competing Products
2 competing products in Sanfilippo Syndrome Type A (MPS IIIA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SOBI003 | Swedish Orphan Biovitrum | Phase 1/2 | 32 |
| rAAV2/5-hNAGLU | uniQure | Phase 1/2 | 26 |